Allstate Corp Invests $614,000 in United Therapeutics Corporation $UTHR

Allstate Corp bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,464 shares of the biotechnology company’s stock, valued at approximately $614,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new position in United Therapeutics during the second quarter valued at $29,000. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Jan Malcolm sold 50 shares of the company’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total value of $25,606.00. Following the transaction, the director directly owned 420 shares in the company, valued at $215,090.40. This represents a 10.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $479.51, for a total transaction of $10,788,975.00. The disclosure for this sale is available in the SEC filing. Insiders sold 563,364 shares of company stock valued at $266,247,272 in the last quarter. Corporate insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright boosted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company lifted their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Royal Bank Of Canada boosted their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $509.50.

United Therapeutics Stock Up 0.5%

UTHR stock opened at $472.06 on Friday. The business’s fifty day simple moving average is $487.61 and its two-hundred day simple moving average is $412.88. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The firm has a market cap of $20.33 billion, a price-to-earnings ratio of 17.89, a PEG ratio of 2.52 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm earned $6.39 earnings per share. Research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.